TY  - JOUR
AU  - Hansen, Niels
AU  - Wiltfang, Jens
TI  - Krankheitsmodifizierende Therapie mit Lecanemab bei früher Alzheimer-Demenz  -  Disease-modifying therapy with lecanemab for early Alzheimer's dementia
JO  - Fortschritte der Neurologie, Psychiatrie
VL  - 93
IS  - 11
SN  - 0720-4299
CY  - Stuttgart [u.a.]
PB  - Thieme
M1  - DZNE-2025-01242
SP  - 453 - 460
PY  - 2025
AB  - Alzheimer's disease (AD) is a severe and progressive neurodegenerative disease of the brain that has so far been treated with symptomatic drug and non-drug therapies as standard treatment. Following the approval of the monoclonal anti-amyloid antibody by the FDA, AD therapy has changed, as this therapy has made it possible to attenuate the biological disease process of AD. Lecanemab has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for approval in patients with early AD under two conditions. Firstly, homozygous ApoE4 carriers and secondly, patients receiving oral anticoagulants should not receive lecanemab. The following narrative review explains the mechanism of action, safety and side effects of lecanemab. Furthermore, risk factors for side effects are described. Finally, the first experiences with lecanemab are reported and the efficacy and financial aspects are discussed. Lecanemab leads to a temporary reduction in amyloid-ß deposits and to a benefit that can be reflected in everyday competence, cognition and quality of life and can be described as a breakthrough in AD's therapy due to its demonstrable biological and clinical efficacy.
KW  - Humans
KW  - Alzheimer Disease: drug therapy
KW  - Alzheimer Disease: psychology
KW  - Antibodies, Monoclonal, Humanized: therapeutic use
KW  - Antibodies, Monoclonal, Humanized: adverse effects
KW  - Amyloid beta-Peptides: metabolism
KW  - Antibodies, Monoclonal, Humanized (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41052542
C2  - pmc:PMC12591830
DO  - DOI:10.1055/a-2681-4558
UR  - https://pub.dzne.de/record/281871
ER  -